Clozapine Improves Memory Impairment and Reduces Aβ Level in the Tg-APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease
- 7 January 2016
- journal article
- research article
- Published by Springer Nature in Molecular Neurobiology
- Vol. 54 (1) , 450-460
Abstract
Alzheimer’s disease (AD) is a progressive degenerative condition. In order to treat AD, the use of a “drug repositioning” or “repurposing” approach with potential disease-modifying compounds has been increased. The new generation antipsychotics are commonly used in AD and other dementias for the treatment of psychosis and behavioral symptoms, and several animal models have shown the effects of these potential disease-modifying compounds. In this study, we examined whether long-term clozapine treatment could reduce amyloid beta (Aβ) deposition and cognitive impairment in transgenic mice of AD, Tg-APPswe/PS1dE9. AD mice were fed clozapine at 20 mg/kg/day for 3 months from 4.5 months of age. Intake of clozapine improved the Aβ-induced memory impairment and suppressed Aβ levels and plaque deposition in the brain of AD mice. Clozapine upregulated Trk, brain-derived neurotrophic factor, cyclin-dependent kinase-5, and p35 in the cortex and hippocampus of AD mice and activated AMP-activated protein kinase (AMPK). As a downstream effector of AMPK, beta-secretase expression was decreased by clozapine administration. Moreover, clozapine-phosphorylated synapsin I at Ser9 and Ser549 sites in the hippocampus and cortex of AD mice, which may be involved in synaptic strength. This study suggests that as one of candidate for multi-target approach of AD treatment, clozapine is proposed as a therapeutic drug for treatment of AD patients.Keywords
This publication has 50 references indexed in Scilit:
- Potential repurposing of oncology drugs for the treatment of Alzheimer's diseaseBMC Medicine, 2013
- Striking reduction of amyloid plaque burden in an Alzheimer's mouse model after chronic administration of carmustineBMC Medicine, 2013
- Brain-Derived Neurotrophic Factor and Neuropsychiatric DisordersPharmacological Reviews, 2012
- Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's diseaseMedicinal Research Reviews, 2011
- Novel synthetic small‐molecule activators of AMPK as enhancers of autophagy and amyloid‐β peptide degradationThe FASEB Journal, 2010
- Involvement of AMP-activated-protein-kinase (AMPK) in neuronal amyloidogenesisBiochemical and Biophysical Research Communications, 2010
- Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's diseaseNature Medicine, 2009
- Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer’s disease mouse models with abundant Aβ in plasmaNeurobiology of Disease, 2006
- Effects of subchronic clozapine administration on serum glucose, cholesterol and triglyceride levels, and body weight in male BALB/c miceLife Sciences, 2005
- Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s diseaseProgress in Neurobiology, 2001